OGN News and Press, Organon & Co. From 04/16/22

Fundamental Diagnosis is an individual investor and former sell-side analyst in healthcare at several top investment banks. The risks of relying too much on the narrative for a stock, how a competitive analysis can serve as a source of idea gen and using a company’s investor pr...

An estimated 21 million American women experience BV Organon (NYSE: OGN), a global women’s healthcare company, and Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced they have entered into an agreement whereby Orga...

Three months into 2022, the markets are in turmoil, and highly priced stocks are falling fast. Investors can look for safety in value-oriented investments that are less vulnerable to sharp declines. The businesses listed here are all profitable and trading at incredibly cheap future earning...

MRK and MO might not seem like they go together too well, but the actual underlying business is what matters for an income investor. MRK has a steady business in the healthcare space, and MO has pricing power. They might originate from two different sectors and be quite opposites,...

SCHD's index both rebalances and reconstitutes its holdings the second Friday in March. SCHD has been adjusting to the recent reconstitution. It added 14 stocks. We look at EOG resources which was the largest new holding and at the sectors represented by the rest of the much smaller s...

Ireland-based self-care company, Perrigo Company (NYSE:PRGO), announced on Thursday that the U.S. Food and Drug Administration (FDA) granted the final approval for over-the-counter use of Nasonex 24HR Allergy. Perrigo (PRGO) identified the approval as its “first branded Rx-to-OTC switc...

Organon & Co. (OGN) 42nd Annual Cowen Health Care Conference March 09, 2022 09:10 AM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Sandra Mulligan - Head, R&D Conference Call Participants Steve Scala - Cowen Michael Nedelcovych - C...

Shares of Organon & Co. (NYSE:OGN) traded today at $38.28, eclipsing its 52-week high. So far today approximately 390,000 shares have been exchanged, as compared to an average 30-day volume of 2.2 million shares. Organon & Co is a science-based global pharmaceutical company that ...

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42 nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST. Investo...

Organon (NYSE: OGN), a global women’s health company, today announced the appointment of Meghan Rivera as US Managing Director. With over 20 years of commercial experience in bio-pharmaceutical organizations and digital therapeutics, Ms. Rivera will be responsible for leading Org...